ERBB2 and breast cancer: In a randomized phase II neoadjuvant GeparSixto trial, Stevic et al. showed that some miRNAs were selectively enriched in the EVs of HER2+ BC and TNBC and that EV-miR-155 and EV-miR-301 were good candidates for predicting pCR [26].